Biagio Ricciuti

Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer

Bairavi Shankar, Jiajia Zhang, Abdul Rafeh Naqash et al. · JAMA Oncology · 2020 · 489 citations · Full text

Medicine, Immunology, Oncology +17

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti et al. · Journal for ImmunoTherapy of Cancer · 2019 · 415 citations · Full text

Medicine, Immunology, Oncology +16

Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels

Biagio Ricciuti, Xinan Wang, Joao V. Alessi et al. · JAMA Oncology · 2022 · 384 citations · Full text

Medicine, Cancer Biology, Oncology +17

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

Biagio Ricciuti, Kathryn C. Arbour, Amir Vajdi et al. · Journal of Thoracic Oncology · 2021 · 367 citations · Full text

Medicine, Molecular Biology, Oncology +17

Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis

Biagio Ricciuti, Carlo Genova, Andrea De Giglio et al. · Journal of Cancer Research and Clinical Oncology · 2018 · 362 citations · Full text

Medicine, Immunology, Oncology +16